ArticleThe Journal of molecular diagnostics : JMD2016
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.
Article in The Journal of molecular diagnostics : JMD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.NPJ breast cancer · 2024Article
- Recommendations related to the analytical equivalence assessment of gene panel testing.Cancer science · 2022Review
- Lentiviral vector-based xenograft tumors as candidate reference materials for detection of HER2-low breast cancer.Frontiers in oncology · 2022Article
- Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements.Clinical chemistry and laboratory medicine · 2019Article
- A model for the impact of FFPE section thickness on gene copy number measurement by FISH.Scientific reports · 2019Article
- Limitations of methods for measuring the concentration of human genomic DNA and oligonucleotide samples.BioTechniques · 2018Article
- Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.Scientific reports · 2017Article
- HER2 mRNA transcript quantitation in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Analytic Response Curves of Clinical Breast Cancer IHC Tests.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017Article
- Perspectives of HER2-targeting in gastric and esophageal cancer.Expert opinion on investigational drugs · 2017Review
- A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.Applied immunohistochemistry & molecular morphology : AIMMArticle
- Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescentSouth Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
The National Institute of Standards and Technology (NIST) Standard Reference Materials 2373 is a set of genomic DNA samples prepared from five breast cancer cell lines with certified values for the ratio of the HER2 gene copy number to the copy numbers of reference genes determined by real-time quantitative PCR and digital PCR. Targeted-amplicon, whole-exome, and whole-genome sequencing measurements were used with the reference material to compare the performance of both the laboratory steps and the bioinformatic approaches of the different methods using a range of amplification ratios. Although good reproducibility was observed in each next-generation sequencing method, slightly different HER2 copy numbers associated with platform-specific biases were obtained. This study clearly demonstrates the value of Standard Reference Materials 2373 as reference material and as a calibrator for evaluating assay performance as well as for increasing confidence in reporting HER2 amplification for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.